Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
Go back to Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome| Corcept Therapeutics, Inc. (NASDAQ: CORT) | Delayed: 113.59 +1.97 (1.76%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $111.62 | 52 Week High | $10.00 | |||
| Open | $108.87 | 52 Week Low | $3.22 | |||
| Day High | $114.06 | P/E | N/A | |||
| Day Low | $108.25 | EPS | $-0.46 | |||
| Volume | 233,390 | |||||
